Endo International plc ENDP beats on both earnings and sales in the first quarter as its Branded Pharmaceuticals segment returned to growth, driven by strong demand for Xiaflex.
The company’s earnings of 73 cents easily beat the Zacks Consensus Estimate of 48 cents in the reported quarter but decreased from 95 cents in the year-ago quarter.
Revenues came in at $717.9 million in the first quarter, surpassing the Zacks Consensus Estimate of $670.47 million but was down 12% from the year-ago quarter due to decreased Generic Pharmaceuticals and Sterile Injectables segment revenues.
Endo International plc Price, Consensus and EPS Surprise
Endo International plc price-consensus-eps-surprise-chart | Endo International plc Quote
Endo has four reportable business segments — Branded Pharmaceuticals, Generic Pharmaceuticals, Sterile Injectables and International Pharmaceuticals.
Branded Pharmaceuticals revenues were $206.6 million compared to $204.1 million in the year-ago quarter. Within the segment, Specialty Products revenues increased 7% to $143.3 million. Sales of Xiaflex increased 7% to $95.3 million. However, Established Products revenues decreased 9% to $63 million.
Sterile Injectables revenues came in at $308.7 million, down 8% year over year due to ongoing generic competition for certain products, partially offset by increased Vasostrict revenues.
Generic Pharmaceuticals reported sales of $181 million in the quarter, down 28% due to continued competitive pressures on certain key products and the impact of COVID-19-related accelerated prescription fulfillment in the year-ago quarter.
International Pharmaceuticals revenues came in at $21.6 million, down 24% year over year due to continued competitive pressures on certain key products.
2021 Guidance Updated
Revenues for 2021 are projected to be $2.65-$2.79 billion compared with the earlier projected range of $2.55-$2.79 billion. Adjusted earnings per share are now estimated to be $1.95-$2.30 (previous estimate: $1.80-$2.30 billion).
Endo reported better-than-expected results for the first quarter as the Branded Pharmaceuticals segment continues to maintain momentum. The company’s efforts to revive its business are encouraging. Last year, the FDA approved QWO (collagenase clostridium histolyticum-aaes) for the treatment of moderate-to-severe cellulite in the buttocks of adult women (anticipated launch in spring). QWO has been launched and the initial uptake seems encouraging.
Shares of Endo have lost 24.4% in the year so far compared with the industry’s 10.9% decline.
Earlier, the company also announced a fill-finish manufacturing and services agreement for Novavax's NVAX COVID-19 vaccine candidate, NVX-CoV2373.
Zacks Rank & A Stock to Consider
Endo currently carries a Zacks Rank # 4 (Sell).
A couple of better-ranked stocks in the healthcare sector include Corcept Therapeutics CORT and Repligen Corporation RGEN. While Repligen carries a Zacks Rank #1 (Strong Buy), Corcept carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Corcept’s earnings estimates have moved up 8 cents for 2021 in the past 90 days.
Repligen’s earnings estimates have increased 25 cents for 2021 in the past 90 days.
+1,500% Growth: One of 2021’s Most Exciting Investment Opportunities
In addition to the stocks you read about above, would you like to see Zacks’ top picks to capitalize on the Internet of Things (IoT)? It is one of the fastest-growing technologies in history, with an estimated 77 billion devices to be connected by 2025. That works out to 127 new devices per second.
Zacks has released a special report to help you capitalize on the Internet ofThings’s exponential growth. It reveals 4 under-the-radar stocks that could be some of the most profitable holdings in your portfolio in 2021 and beyond.
Click here to download this report FREE >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Endo International plc (ENDP) : Free Stock Analysis Report
Novavax, Inc. (NVAX) : Free Stock Analysis Report
Repligen Corporation (RGEN) : Free Stock Analysis Report
Corcept Therapeutics Incorporated (CORT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research